Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b single-arm, open-label, study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in acute myeloid leukemia patients in complete response with measurable residual disease

Next Previous
Trial Profile

A phase 1b single-arm, open-label, study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in acute myeloid leukemia patients in complete response with measurable residual disease

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emavusertib (Primary) ; Azacitidine; Venetoclax
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions

Most Recent Events

  • 05 Nov 2025 According to a Curis media release, data from the trial will be presented at the 67th ASH Annual Meeting in December:
  • 31 Mar 2025 According to a Curis media release, results of this trial were published in a financial report.
  • 31 Mar 2025 According to a Curis media release, company initiated the study and first dosing cohort was completed and well tolerated, with no unexpected adverse events. The external Clinical Safety Review Committee recommended escalation to the next dosing cohort. Enrollment for this cohort is currently ongoing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top